Clinical Trials Logo

Acne Vulgaris clinical trials

View clinical trials related to Acne Vulgaris.

Filter by:

NCT ID: NCT04829370 Completed - Atrophic Acne Scar Clinical Trials

Clinical Application of Patented Lyophilized PLT in Acne Scar Repairment.

Start date: March 20, 2020
Phase: N/A
Study type: Interventional

All kinds of skin problems will cause a person's life caused by varying degrees of trouble, especially issues at face. No matter diseases or aging would cause mental pressure and the inconvenience in different ages. Scar caused by acne is the most common skin issue amount young people. While acne recovering, due to the destruction of collagen forming fibrous tissue, and scars be left. Clinical treatments are facial laser, argon laser and carbon dioxide laser. With the combination of rejuvenation to accelerate growth of collagen when needed. According to journal articles, facial laser combined with Platelet-rich plasma is more curative than facial laser treatment alone and can significantly reduce side effects (Dermatol Surg. 2014 Feb;40(2):152-61). Platelet has been valued in regeneration medicine due to its various growth factors with repairment, induction and promotion functions. Moreover, low risk of allergy for it is an autologous material. Platelet had been officially applied in orthopedics and more clinical studies in many other fields. Nowadays, preparation of PRP is by single-use centrifuge tube, patients have to go through blood collection process every time before therapy due to short shelf life of PRP. Meanwhile, amount of platelet in PRP would be different due to difference of individual, health condition and separation methods. Thus, leaving unknown of active principle and uncertainty of treatments. In this trial, a patented technique of lyophilized PLT preparation method is applied, collect 250 c.c. of blood specimen by using blood bag, separate platelet in germ-free clean room, then lyophilize platelet to extend shelf life to at least three years after quantifying platelet amount. Therefore, treatment could be done after simple dissolution process of PLT leads to the convenience of multiple therapy lessons.

NCT ID: NCT04820673 Not yet recruiting - Acne Vulgaris Clinical Trials

Patient-reported Outcomes for Sarecycline Effectiveness and Safety (PROSES)

PROSES
Start date: June 2021
Phase:
Study type: Observational

The purpose of this study is to evaluate the patient-reported outcomes (PROs) in terms of health-related quality of life (HRQoL) and signs of Acne Vulgaris (AV) among patients with moderate to severe non-nodular AV who are administered sarecycline (Seysara®) in real-world community practice settings in the United States (U.S). Investigator's Global Assessment (IGA) of AV and safety measures associated with use of sarecycline (Seysara®) will be assessed over the study observation period of 12 weeks. Clinicians will prescribe sarecycline (Seyara®) as per their own clinical judgment and standard practice.

NCT ID: NCT04807179 Enrolling by invitation - Acne Scars Clinical Trials

Clinical Study to Evaluate Alexandrite Laser for the Treatment of Acne Scars

Start date: March 8, 2021
Phase: N/A
Study type: Interventional

The intended use of the Alexandrite laser device used in this study is to assess the efficacy and safety of the Alexandrite laser device for the treatment of acne scars on skin types V and VI.

NCT ID: NCT04806594 Recruiting - Acne Clinical Trials

Clinical Investigation on the Safety and Clinical Performance of Papix Acne Scar.

Start date: September 25, 2020
Phase: N/A
Study type: Interventional

The scope of this open label clinical trial is to evaluate and confirm the performance of Papix acne scar in the prevention and improvement of acne scars in subject suffering for mild to moderate acne. The product will be applied for 8 consecutive weeks and 3 clinical follow up visits will be performed.

NCT ID: NCT04797793 Completed - Acne Vulgaris Clinical Trials

A Study Comparing Adapalene Gel 0.1% and to Differin Gel in the Treatment of Acne Vulgaris

Start date: May 18, 2020
Phase: Early Phase 1
Study type: Interventional

To demonstrate therapeutic equivalence and safety of adapalene gel 0.1% (Taro Pharmaceuticals U.S.A., Inc.) and Differin® Gel (Adapalene Gel 0.1%, Galderma) in the treatment of acne vulgaris.

NCT ID: NCT04730414 Not yet recruiting - Acne Vulgaris Clinical Trials

Full Spectrum Hemp Observational Study

Start date: February 2021
Phase:
Study type: Observational [Patient Registry]

In westernized societies, acne vulgaris is nearly a universal skin disease afflicting 79% to 95% of the adolescent population; older than 25 years - 40% to 54% have facial blemishes and persists into middle age in 12% of women and 3% of men. Standard treatment modalities present with high risk morbidities. Charlotte's Web hemp blemish product is predicted to significantly reduce the risks mentioned above, while improving efficacy as well as imparting other skin benefits.

NCT ID: NCT04724473 Completed - Acne Vulgaris Clinical Trials

A Study Comparing Tretinoin Cream 0.025% and RETIN-A® Cream 0.025% in the Treatment of Acne Vulgaris

Start date: December 10, 2019
Phase: Early Phase 1
Study type: Interventional

The bioequivalence and safety of Tretinoin Cream 0.025% (Taro Pharmaceuticals U.S.A, Inc.) and RETIN-A® (Tretinoin) Cream 0.025% in the treatment of acne vulgaris.

NCT ID: NCT04709289 Completed - Acne Vulgaris Clinical Trials

Adverse Effects of ALA-PDT for the Treatment of Moderate to Severe Acne Vulgaris: a Prospective Study

Start date: January 1, 2020
Phase: N/A
Study type: Interventional

To understand, prevent and treat the adverse reactions more comprehensively, we sought to systemically document the adverse effects of ALA-PDT for moderate to severe acne vulgaris.

NCT ID: NCT04698239 Completed - Acne Vulgaris Clinical Trials

Clinical Evaluation of the Safety and Benefits of the Milesman 445 nm Blue Laser on Inflammatory Acne Lesions.

Start date: September 24, 2020
Phase: N/A
Study type: Interventional

Acne treatment by laser or other light devices is a currently accepted procedure. It allows faster resolution of injuries, with fewer side effects and greater patient satisfaction. The mechanism of action of the Milesman Blauman laser is based on diode laser technology that produces pulses of blue light with a wavelength of 445 nanometers, in the blue and visible spectrum. It combines the precision of laser technology by focusing energy on diseased areas.

NCT ID: NCT04648995 Not yet recruiting - Acne Scar Clinical Trials

TheTreatment of Acne Scar Using UltraPulse CO2 Laser

Start date: December 15, 2020
Phase: N/A
Study type: Interventional

Purpose of the study is to assess the effect and evaluate topographic volume changes of UltraPulse at treating boxcar scars with different energy and the effect of UltraPulse at treating icepick scars.